NCT06558799Phase 2Terminated

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Study sponsor: NovoCure GmbH

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-02-23Actual
Enrollment · participants31Actual
Source updated2026-06-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 69 participants (planned). After: 31 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 31 Jan 2026. After: 23 Feb 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview